FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection By Ogkologos - October 2, 2025 329 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study MK-3475A-D77 Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Five Fraction SBRT Noninferior to Moderately Fractionated Image-Guided Radiotherapy for Patients... November 7, 2024 EMA Recommends Extension of Therapeutic Indications for Atezolizumab May 24, 2022 Breast Cancer Vaccine Has Eliminated Cancer In Its First Human Patient December 16, 2019 Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with... January 9, 2026 Load more HOT NEWS NRG1 Fusion–positive Lung Cancers are Molecularly, Pathologically, and Clinically More Heterogeneous... Breast Cancer May Spread by Recruiting Nearby Sensory Nerves EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR... Cancer Patients May Soon Be Able to Get an Entire Course...
